Inclusion Criteria:
* Male and female adults who are between 18 - 65 years of age (inclusive) at the time of signing the informed consent.
* Have a BMI range of 18.0 - 29.9 kg/m2 (inclusive)
* Weigh no less than 50 kilograms.
* Are able to consume all aspects of the O3-SACT.
* Are able to consume all standardized in-clinic meals provided.
* Are able to consume the assigned study product and study components.
* Regularly consumes 3 meals a day.
* Have FE-1 levels that are between 100 - 300 μg/g within 12 months of screening.
* Have a presence of gastrointestinal (GI) symptoms as confirmed by a GSRS total score between 2 and 5 (inclusive) at screening.
* Have hematological, serum, and urine parameters within normal limits or not clinically significant, as determined by the investigator.
* Must have suitable veins for repeated venipuncture.
* Non-smokers (including nicotine vaping) and have not used any nicotine products (patches, gums, etc.) for \> 3 months prior to Visit 2. Non-smoker is defined as someone who does not habitually/regularly use products containing nicotine and willing to abstain for 14 days before Visit 2 until the last procedure.
* Agree to fast overnight, i.e., no food or liquids (except for water, permitted up to 15 min prior to dosing) for a minimum of 12 h prior to each post-screening visit.
* In otherwise good general health, as deemed by the investigator (based on a review of medical history, vital signs, laboratory safety tests, and physical examination if performed at screening).
* Have maintained consistent dietary habits, including medication and supplement intake, and lifestyle for the last 3 months before screening and agree to maintain them throughout the study (unless required per the restrictions).
* Agree, from screening until 30 days (for individuals of CBP) or 90 days (for individuals with the potential to impregnate others) after study product administration, to use acceptable contraceptive methods and have negative pregnancy tests if of CBP.
* Agree to follow the restrictions on concomitant treatments.
* Agree to follow the restrictions on lifestyle.
* Willing and able to agree to the requirements of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.
Exclusion Criteria:
* Individuals of CBP who are pregnant, intending to breastfeed, or intending to conceive at the time of consent and during the study, or demonstrate a positive pregnancy test.
* Have a known sensitivity, intolerability, or allergy to any of the study products or their excipients or any of the study components.
* Have participant reported Type I diabetes, Type II diabetes, high blood pressure (≥140 systolic or ≥90 diastolic mmHg), or thyroid disease.
* Have participant reported current diagnosis of a disease causing chronic or recurrent muscle breakdown (e.g., inflammatory myositis, muscular dystrophy, dermatomyositis)
* Have had recent major muscle-related injury within the past 4 weeks prior to screening (e.g., bone fracture, crush injury, deep soft-tissue injury).
* Have current symptoms, or symptoms within the past 7 days, of an acute infection (e.g., fever, respiratory symptoms such as persistent cough or difficulty breathing), that may influence study outcomes as assessed by the investigator.
* Have participant reported history or current diagnosis of cystic fibrosis.
* Have clinically significant abnormal laboratory values at screening, including aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 5× ULN, alkaline phosphatase \> 2× ULN, estimated glomerular filtration rate (eGFR) ≤ 60 mL/min/1.73 m², urine protein ≥ 30 mg/dL, or International Normalized Ratio (INR) ≥ 1.2.
* Have participant reported history of prior gastrointestinal surgery (e.g., gastric bypass, gastrectomy, gastric banding, or other visceral surgery) that may interfere with normal gastrointestinal anatomy or function or confound study results.
* Have participant reported history or current diagnosis of eating disorders such as anorexia or bulimia.
* Have participant reported history of or current use of any prescribed or non-prescribed medication that could potentially interfere with gastric pH, intestinal motility, or fat absorption, including herbal and dietary supplements and antacids. These medications will be discontinued for a minimum of five times their half-life prior to study product administration.
* Have a lifestyle incompatible with the trial, such as adherence to extreme diets (e.g., hypocaloric, ketogenic), participation in intense physical activity exceeding 10 hours per week, or any other lifestyle factors as determined by the investigator.
* Have medical condition(s) known to interfere with absorption, distribution, metabolism, or excretion of the study product (e.g., Crohn's disease, short bowel syndrome, ulcerative colitis, irritable bowel syndrome \[mixed, constipation-predominant, diarrhea-predominant\], or celiac disease).
* Have a history of heart/cardiovascular disease, renal disease (dialysis or renal failure), hepatic impairment/disease, immune disorders and/or immunocompromised (i.e., HIV/AIDS).
* Have a history of cancer (except localized skin cancer without metastases or in situ cervical cancer), unless recovery occurred more than 5 years before the screening visit.
* Are receiving treatments for or have been hospitalized in the last 12 months for psychiatric disorders (e.g., depression, bipolar disorder, schizophrenia, etc.) that may affect the participant's capability to carry out all procedures of the study at the investigator's discretion.
* Major surgery in 3 months prior to screening or planned major surgery during the study.
* Have a history of alcohol (more than 14 units per week) or substance abuse in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program) or use that in the opinion of the investigator may be of a concern for the study.
* Current enrollment or past participation in another study with any product(s) with at least one active ingredient within 28 days before Visit 2 or longer, if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of current study.
* Any other medical condition/situation or use of medications/supplements/therapies that, in the opinion of the investigator, may adversely affect the participant's ability to participate in the study or its measures or pose a significant risk to the participant.
